Solural Pharma ApS publish clinical results for its oral irinotecan product in combination with capecitabine in Cancer Chemotherapy and Pharmacology: An open label phase 1 study evaluating safety, tolerability and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine
Recent news
- New patent acquisition agreement November 16, 2022
- New Eurasia patent December 25, 2020
- New Manufacturing Authorisation December 18, 2020
Career
If you are interested in joining Solural Pharma ApS, we are seeking professionals, technicians and consultants with expertise within drug development. Please contact
career@soluralpharma.com for more information about available positions.